Founded in 1987 but not SBIR involved for several years and then on a limited basis, Novavax, Inc. is headquartered in Gaithersburg, MD functioning as a clinical-stage biopharmaceutical company that came into existence after IGI Labs, Inc (AMEX:IGI) divested itself of its biotech division to its stockholders ...immediately making the new firm a publicly traded entity. Novavax, Inc., together with its subsidiary, Novavax AB - a late-stage biotechnology company - organizes around discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates had included ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. The firm's lead adjuvant has been Matrix-M - used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company also developed RSV F vaccine for older adults (60 years and older) that went through Phase II clinical trial, as well as for healthy children between six months to five years of age. In addition, the firm develops nanoparticle vaccine candidates for clinic testing against ebola virus also taken through Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company developed COVID-19 vaccine for the coronavirus that had cause pneumonia-like symptoms. The firm also had a co-marketing agreement with GE Healthcare for a pandemic influenza vaccine solution,
